Last reviewed · How we verify
NCT06327997
An Exploratory Study by Fast CAR T Cells
EARLY_PHASE1 trial testing Fast CAR T cells in Solid Tumor in 20 participants. Currently enrolling.
6 March 2027
Quick facts
| Lead sponsor | Shanghai Cell Therapy Group Co.,Ltd |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 7 March 2024 |
| Primary completion | 6 March 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Fast CAR T cells — full drug profile →
Conditions studied
- Solid Tumor — all drugs for Solid Tumor →
Sponsor
Shanghai Cell Therapy Group Co.,Ltd — full company profile →
Who can join
Adults 18 to 70, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main goal of this trial is to evaluate the safety and tolerability of CAR T cell therapy for advanced solid tumors with positive mesothelin and MUC1.Patients were screened, peripheral blood mononuclear cells (PBMC) were isolated from eligible patients, and cells were prepared. Pretreatment was performed within 5 days before infusion, and CAR T cells were infused on day 0 (the dose was determined according to the requirements of climbing/expansion). The safety intensive observation period was 28 days after infusion, and the clinical efficacy after infusion was evaluated on days 28-34. The follow-up observation and evaluation were carried out according to the follow-up visit point, and the follow-up period was 1 year. From the second year, the telephone follow-up period was entered.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Mucin-1: a promising pan-cancer therapeutic target.
Grewal US, Kurzrock R. · · 2025 · cited 12× · PMID 40604087 · DOI 10.1038/s41698-025-01016-2 -
Adoptive T‐cell therapies in the clinic
Shaha S, Lourenco L, Zhao Z, Mitragotri S. · · 2025 -
Mesothelin biology and the evolving landscape of targeted immunotherapy.
Boisgard R, Chames P, Kerfelec B. · · 2026 · PMID 41994562 · DOI 10.1016/j.omton.2026.201148
Verify or expand the search:
- PubMed search for NCT06327997
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fast CAR T cells
Trials testing the same drug.
- NCT06249256 — An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells · EARLY_PHASE1 · recruiting
Other recruiting trials for Solid Tumor
Currently open trials in the same condition.
- NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
- NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
- NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting
Other Shanghai Cell Therapy Group Co.,Ltd trials
Trials by the same sponsor.
- NCT07479667 — An Antibody-armored Dendritic Cell in Patients With Solid Tumors · Phase 1 · recruiting
- NCT07146672 — Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors · Phase 1, PHASE2 · recruiting
- NCT07414381 — An Exploratory Study of Chenghuang Circadian Rhythm Regulator in Subjects With Sleep Disorders · NA · completed
- NCT06732232 — A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
- NCT06446128 — A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06327997 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Cell Therapy Group Co.,Ltd
- Last refreshed: 25 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06327997.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing